Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes for a digital prescription mobile application for adults with irritable bowel syndrome: an uncontrolled trial.

BMC gastroenterology·2026
Same author

A systemic concern with arterial blood gas analysers in patients with increased temperatures that has the potential to adversely impact on patient care: an observational study.

Emergency medicine journal : EMJ·2026
Same author

Changing trends in androgen deprivation therapy prescribing for prostate cancer in England, 2015-2024.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Diagnosis of inflammatory bowel disease after symptomatic faecal immunochemical testing: population-based cohort study.

The British journal of surgery·2026
Same author

Occurrence and persistence of symptoms, diagnoses and prescriptions after community-diagnosed COVID-19: a matched cohort study using the OpenSAFELY platform.

Journal of epidemiology and community health·2026
Same author

Real-world data in the absence of RCTs: the case for DOACs.

Blood advances·2026

Related Experiment Video

Updated: Mar 29, 2026

Detecting Anastasis In Vivo by CaspaseTracker Biosensor
20:16

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Published on: February 1, 2018

9.8K

Adrenergic blockers and the risk for common solid cancers: a case-control study.

Beade Numbere1, Kate M Fleming, Alex Walker

  • 1aDivision of Epidemiology and Public Health, School of Medicine bNottingham Digestive Diseases Centre, NIHR Biomedical Research Unit, University of Nottingham, Nottingham, UK.

European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)
|December 10, 2015
PubMed
Summary

Adrenergic blockers, used in laboratory studies to inhibit cancer cell growth, showed no protective effect on common cancer incidence in a large epidemiological study. The research found a slightly increased risk for colorectal and breast cancers, possibly due to confounding factors.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Experiment Videos

Last Updated: Mar 29, 2026

Detecting Anastasis In Vivo by CaspaseTracker Biosensor
20:16

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Published on: February 1, 2018

9.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Area of Science:

  • Pharmacology and Oncology
  • Epidemiology
  • Clinical Research

Background:

  • Laboratory studies suggest adrenergic blockers may inhibit cancer cell proliferation and migration.
  • Epidemiological evidence on the effect of adrenergic blockers on cancer incidence has been inconsistent.
  • A need exists to clarify the association between adrenergic blocker use and common cancer risk.

Purpose of the Study:

  • To assess the effect of adrenergic blockers on the incidence of prostate, lung, colorectal, and breast cancers.
  • To investigate potential protective or detrimental effects of adrenergic blockade on common cancer development.
  • To provide robust epidemiological data on adrenergic blockers and cancer risk.

Main Methods:

  • A case-control study was conducted using the Clinical Practice Research Datalink.
  • Incident cases of prostate, lung, colorectal, and breast cancers were identified, with controls frequency-matched by age (10:1).
  • Logistic regression adjusted for age, sex, smoking, alcohol use, comorbidities, and coprescriptions.

Main Results:

  • No evidence of a protective effect was found for lung and prostate cancers.
  • A slightly increased risk was observed for colorectal and breast cancers in users of adrenergic blockers.
  • Final odds ratios for beta-blocker exposure were 0.99 (lung), 1.14 (colorectal), 1.10 (breast), and 1.01 (prostate).
  • Final odds ratios for alpha-blocker exposure were 1.03 (lung), 1.13 (colorectal), and 1.08 (breast).

Conclusions:

  • Adrenergic blocker use does not appear to prevent common cancers.
  • A slightly increased risk for colorectal and breast cancers was noted, potentially due to residual confounding.
  • Further research may be needed to fully understand the complex relationship between adrenergic blockers and cancer risk.